Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents (Q37649249)

21 August 2017

1 reference

title

Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents (English)

1 reference

21 August 2017

Jessica Adams

1

1 reference

21 August 2017

Nimish Patel

2

1 reference

21 August 2017

Nancy Mankaryous

3

1 reference

21 August 2017

Mariam Tadros

4

1 reference

21 August 2017

Christopher D Miller

5

1 reference

21 August 2017

language of work or name

English

0 references

publication date

8 December 2009

1 reference

Annals of Pharmacotherapy

21 August 2017

1 reference

21 August 2017

44

1 reference

21 August 2017

157-165

1 reference

21 August 2017

1

1 reference

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 August 2017

1 reference

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

21 January 2018

1 reference

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

21 January 2018

1 reference

Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview

21 January 2018

1 reference

First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort

21 January 2018

1 reference

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure

21 January 2018

1 reference

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

21 January 2018

1 reference

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

21 January 2018

1 reference

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects

21 January 2018

1 reference

Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors

21 January 2018

1 reference

In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).

21 January 2018

1 reference

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.

21 January 2018

1 reference

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial

21 January 2018

1 reference

Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues

21 January 2018

1 reference

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations

21 January 2018

1 reference

Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains

21 January 2018

1 reference

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects

21 January 2018

1 reference

New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.

21 January 2018

1 reference

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M359

1 reference

21 August 2017

1 reference